Lafont A, Sinnaeve PR, Cuisset T, et al. - Given that a 29% attenuation in the rate of all‐cause death, myocardial infarction, stroke, and ischaemia‐driven target lesion revascularization at 1 year was reported in relation to treatment with percutaneous coronary intervention (PCI) with drug eluting stent (DES) and a short span of P2Y12 inhibitor (1 and 6 months for stable and unstable coronary syndromes, respectively) vs bare metal stents (BMS) in the SENIOR trial, this present study was undertaken to report results at 2 years. In a randomized manner, 596 [50%] patients were assigned to the DES group and 604 [50%] to the BMS group. According to the findings, a reduction in revascularization up to 2 years, along with very few late events and without any increase in bleeding complications or stent thrombosis, was afforded by a strategy combining a DES together with a short duration of DAPT vs BMS in elderly PCI patients.